ARTICLES BY LOUIS

• Can Biomanufacturing Support U.S. Cities?

  11/1/2021

  Are big cities in the U.S. amenable to biomanufacuting operations? Are they great places to live and work? I have some doubts. In a recent discussion, [Joseph Fetterman](https://www.colliers.com/en/experts/joseph-fetterman), Executive Vice President, Colliers Life Sciences, tried to disabuse me of them. He has the blueprint to demonstrate his optimism. 

• $10 Billion And 1 Million Liters: Here Comes The Biomanufacturing Capacity!

  10/28/2021

  Remember when a lack of capacity was going to feel like a massive concrete slab blocking the road to a biopharmaceutical revolution? Instead, it's felt like so many bricks placed in the paths of individual drug development programs. Now CDMOs are building to meet demand. Is it the right kind of capacity?

• Car Parts To CAR T: Biomanufacturing Redevelopment In Philly

  10/22/2021

  2.4 million sq ft of dormant industrial space undergoing adaptive reuse development as a biomanufacturing center in the heart of Philadelphia. Do we have your attention? Cell and gene therapy companies, CDMOs, Big Pharma: All are welcome to the renaissance.

• Cell And Gene Start-Ups Need "CDMO 2.0"

  10/18/2021

  Today, cell-and-gene companies need knowledge support, and thus a “new sort of consultancy partnership focused on process development and advice-giving, not just routine CDMO contracts for services.” “CDMO 2.0” can materialize in an increasingly familiar form – drug-developer/service-provider hybrid organization.

• Creating The Culture Of Cell Culture

  10/12/2021

  Massimo Dominici is on a mission to “GMP-ify” the cell-and-gene industry, and create a ubiquitous new “culture of cell culture,” as he puts it. To do that, the company he co-founded set out as an emerging, clinical-stage biopharma, and also became a service provider to other emerging CGT developers.

• How To Coordinate Your Site Selection With State Economic Development

  10/7/2021

  Happy about it or otherwise, many readers will face a level of “site selection” – some of you coming face-to-face with economic development agencies at state, regional or local levels. What should you expect? We've got answers and advice.

• Should You Build Where You Buy? A Rarely Discussed Model For Biopharma

  9/23/2021

  You are an emerging biopharma outsourcing to a trusted CDMO that has selected its location wisely – an important factor in your selecting it. Now you’ve determined to establish some of your own development or manufacturing facilities. Would it be beneficial to build close to your CDMO?

• “Relational Contract” Supports Outsourcing Of Hepatitis B Immunotherapy

  9/16/2021

  With a more flexible and relational approach, CDMOs and emerging drug sponsors can end up putting together a different contract altogether – one driving a new pricing and calculation that works for both sides. Here's details to one example.

• Surprise! CEOs Select CDMOs

  9/13/2021

  Somebody has to set the strategic integration of in-house development and manufacturing with external activities; identify for investors why that is the wisest strategy; explain why the CDMO selected is the best fit. Those somebodies are CEOs. Here’s more from ISR Reports.

• Do You Understand The Motives of Your Advisors?

  9/8/2021

  What's really in it for your independent advisors and board members? We've some firsthand answers that will catalyze some thoughts on how you receive potentially invaluable advice from a trusted executive-level mentor, advisor, and additive governing voice – and not only regarding outsourcing.